ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Phase 2

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: AGN-214868
Drug: AGN-214868 placebo

First Posted Date: 2010-07-07

Last Posted Date: 2014-03-19

Lead Sponsor: Allergan

Target Recruit Count: 160

Registration Number: NCT01157377

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

Phase 4

Terminated

Conditions: Glaucoma, Angle-Closure

Interventions: Drug: brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution
Drug: latanoprost

First Posted Date: 2010-06-29

Last Posted Date: 2013-02-06

Lead Sponsor: Allergan

Target Recruit Count: 17

Registration Number: NCT01151904

Safety Study of LiRIS in Interstitial Cystitis (IC) Patients

Phase 1

Completed

Conditions: Interstitial Cystitis

Interventions: Drug: LiRIS low dose and LiRIS high dose

First Posted Date: 2010-06-25

Last Posted Date: 2014-11-25

Lead Sponsor: Allergan

Target Recruit Count: 18

Registration Number: NCT01150565

Locations: 🇨🇦
Queen Elizabeth II Health Sciences Centre, Halifax Infirmary, Halifax, Nova Scotia, Canada
🇨🇦
Centre for Applied Urological Research, Kingston, Ontario, Canada
🇨🇦
Dr. Steinhoff Clinical Research, Victoria, British Columbia, Canada

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Phase 2

Completed

Conditions: Neuralgia, Postherpetic

Interventions: Drug: Placebo to AGN-214868
Drug: AGN-214868

First Posted Date: 2010-05-24

Last Posted Date: 2013-11-15

Lead Sponsor: Allergan

Target Recruit Count: 294

Registration Number: NCT01129531

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Phase 2

Terminated

Conditions: Subfoveal Choroidal Neovascularization
Age-Related Maculopathy

Interventions: Drug: 700 ug dexamethasone
Biological: ranibizumab
Other: sham

First Posted Date: 2010-05-13

Last Posted Date: 2012-09-05

Lead Sponsor: Allergan

Target Recruit Count: 4

Registration Number: NCT01122511

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Ocular Hypertension
Primary Open-Angle Glaucoma

Interventions: Drug: AGN-210961 Formulation 2
Drug: AGN-210961 Formulation 1
Drug: AGN-210961 Formulation 4
Drug: AGN-210961 Formulation 7
Drug: bimatoprost ophthalmic solution 0.03%
Drug: AGN-210961 Formulation 3
Drug: AGN-210961 Formulation 5
Drug: AGN-210961 Formulation 6

First Posted Date: 2010-04-26

Last Posted Date: 2014-08-05

Lead Sponsor: Allergan

Target Recruit Count: 163

Registration Number: NCT01110499

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Phase 2

Completed

Conditions: Pterygium

Interventions: Drug: cyclosporine ophthalmic emulsion 0.05%
Drug: Vehicle

First Posted Date: 2010-04-22

Last Posted Date: 2012-06-25

Lead Sponsor: Allergan

Target Recruit Count: 115

Registration Number: NCT01109056

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: botulinum toxin Type A
Drug: Normal saline

First Posted Date: 2010-04-21

Last Posted Date: 2019-05-03

Lead Sponsor: Allergan

Target Recruit Count: 315

Registration Number: NCT01107392

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: Bimatoprost 0.03% Formulation B Ophthalmic Solution
Drug: Bimatoprost 0.03% Ophthalmic Solution

First Posted Date: 2010-04-08

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 597

Registration Number: NCT01099774

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Phase 4

Completed

Conditions: Overactive Bladder

Interventions: Drug: trospium chloride
Drug: placebo

First Posted Date: 2010-03-19

Last Posted Date: 2013-09-26

Lead Sponsor: Allergan

Target Recruit Count: 322

Registration Number: NCT01089751

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy